Every-2-Weeks Dosing to Help Fight ALL

A nurse administers IV treatment to an acute lymphoblastic leukemia patient.

Here's what you need to know

ONCASPAR offers the option of every-2-weeks asparaginase dosing when used as part of a multicomponent chemotherapy regimen.

You will receive ONCASPAR at your healthcare professional's office and it may be given by either an injection into a muscle (intramuscular, or IM) or an infusion into a vein (intravenous, or IV).

ONCASPAR is engineered to stay in the body longer through a process called PEGylation, which means that every dose lasts longer in the fight against acute lymphoblastic leukemia (ALL).

What to expect during treatment

Some people may have allergic, nonallergic, or silent allergic reactions to ONCASPAR. Your healthcare professional may use a type of testing called therapeutic drug monitoring (TDM) to help figure out the type of reaction it was. If you have a nonallergic reaction, you may be able to continue your ONCASPAR treatment.

To lower your chances of having a reaction to ONCASPAR, your healthcare professional may use an approach called "premedication," which means you will receive medications before you start your ALL treatment. These medications may prevent or reduce allergic reaction symptoms.

fewer treatment reactions

One evaluation showed a 66% reduction in treatment reactions when patients were given medication before treatment.

Many patients have benefitted from the use of premedication and TDM, which are also recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).*

Staying the course

Patients who remained on asparaginase treatment as part of an ALL chemotherapy regimen had significantly better survival compared with patients who stopped asparaginase treatment.

Abbreviation: NCCN, National Comprehensive Cancer Network.

Learn more about patient support resources

LEARN MORE

An acute lymphoblastic leukemia patient sits and talks with their friend over coffee.

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed July 26, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Acute Lymphoblastic Leukemia V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 3, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

IMPORTANT SAFETY INFORMATION

ONCASPAR should not be given to patients who have had:

Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients
Serious blood clots, serious swelling of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment
Serious impairment of liver function

IMPORTANT SAFETY INFORMATION

ONCASPAR should not be given to patients who have had:

Serious allergic reactions to ONCASPAR (pegaspargase) or any of its ingredients
Serious blood clots, serious swelling of the pancreas (abdominal pain), or serious bleeding during previous L-asparaginase treatment
Serious impairment of liver function

ONCASPAR may cause serious side effects including:

Allergic reactions (Symptoms: hives and itching, a swollen tongue or throat, trouble breathing, dizziness, fainting)
Swelling of the pancreas (Symptoms: severe stomach pain, nausea, vomiting, fever, chills, diarrhea)
Blood clots (Symptoms: severe headache, arm or leg swelling, shortness of breath, chest pain)
Increased/excess sugar in the blood (Symptoms: Excessive thirst, increased amount of urine or urinary frequency)
Unusual bleeding or bruising
Abnormal liver function or damage (Symptoms: jaundice, severe nausea, vomiting)

Call or see your doctor right away if you develop any of these serious side effects or if symptoms get worse.

Before receiving ONCASPAR, tell your doctor about all your medical conditions, including if you:

are pregnant or plan to become pregnant. ONCASPAR can harm your unborn baby. You should not become pregnant during treatment with ONCASPAR. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with ONCASPAR.
Females who are able to become pregnant: You should use effective non-hormonal birth control (contraception) during treatment with ONCASPAR and for at least 3 months after the last dose.
are breastfeeding or plan to breastfeed. It is not known if ONCASPAR passes into your breast milk. Do not breastfeed during treatment with ONCASPAR and for 1 month after your last dose.

How will I receive ONCASPAR?

ONCASPAR will be given to you as an injection by your doctor as part of your chemotherapy treatment plan. It is important that you receive all of your treatment doses according to your doctor’s instructions.
During treatment, you will be monitored, and if you experience side effects, your doctor may have to change your treatment.

The most common side effects of ONCASPAR include: low albumin blood level (hypoalbuminemia), elevated liver enzymes, fever with low white blood cell count, abnormal elevation of triglyceride levels in the blood (hypertriglyceridemia), a high level of blood sugar (hyperglycemia), increased bilirubin level, swelling of the pancreas, abnormal clotting studies, embolic and thrombotic events, allergic reactions, sepsis, and infections.

This is not a complete list of side effects that may occur. Call your doctor for medical advice about any side effects especially if they do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit

, or call 1-800-FDA-1088. You may also report side effects to Servier Pharmaceuticals LLC at 1-800-807-6124.

For additional information, please refer to the ONCASPAR Full Prescribing Information and discuss any questions with your doctor.

ONCASPAR is a registered trademark of Servier IP UK Ltd., a wholly-owned, indirect subsidiary of Les Laboratoires Servier. Servier and the Servier logo are registered trademarks of Les Laboratoires Servier.